Search

Your search keyword '"Sensebé L"' showing total 145 results
Start Over Author "Sensebé L"
145 results on '"Sensebé L"'

1. Intramyocardial transplantation of mesenchymal stromal cells for chronic myocardial ischemia and impaired left ventricular function: Results of the MESAMI 1 pilot trial

Author

Guijarro, D., Lebrin, M., Lairez, O., Bourin, P., Piriou, N., Pozzo, J., Lande, G., Berry, M., Le Tourneau, T., Cussac, D., Sensebe, L., Gross, F., Lamirault, G., Huynh, A., Manrique, A., Ruidavet, J.B., Elbaz, M., Trochu, J.N., Parini, A., Kramer, S., Galinier, M., Lemarchand, P., and Roncalli, J.

Published
2016
Full Text
View/download PDF

8. Donor selection and release criteria of cellular therapy products

Author

Eichler, H., Schrezenmeier, H., Schallmoser, K., Strunk, D., Nystedt, J., Kaartinen, T., Korhonen, M., Fleury-Cappellesso, S., Sensebé, L., Bönig, H., Rebulla, P., Giordano, R., Lecchi, L., Takanashi, M., Watt, S. M., Austin, E. B., Guttridge, M., McLaughlin, L. S., Panzer, S., and Reesink, H. W.

Published
2013
Full Text
View/download PDF

12. A randomized controlled clinical trial evaluating the performance and safety of platelets treated with MIRASOL pathogen reduction technology

Author

Cazenave, J-P., Folléa, G., Bardiaux, L., Boiron, J.-M., Lafeuillade, B., Debost, M., Lioure, B., Harousseau, J-L., Tabrizi, R., Cahn, J.-Y., Michallet, M., Ambruso, D., Schots, R., Tissot, J.-D., Sensebé, L., Kondo, T., McCullough, J., Rebulla, Paolo, Escolar, Gines, Mintz, P., Heddle, N. M., Goodrich, R. P., Bruhwyler, J., Le, C., Cook, R. J., and Stouch, B.

Published
2010
Full Text
View/download PDF

18. ING1b negatively regulates HIF1α protein levels in adipose-derived stromal cells by a SUMOylation-dependent mechanism

Author

Bigot, N, Guérillon, C, Loisel, S, Bertheuil, N, Sensebé, L, Tarte, K, Pedeux, R, Université de Rennes 1 (UR1), Université de Rennes (UNIV-RENNES), Microenvironnement et cancer (MiCa), Université de Rennes (UNIV-RENNES)-Université de Rennes (UNIV-RENNES)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Structure Fédérative de Recherche en Biologie et Santé de Rennes ( Biosit : Biologie - Santé - Innovation Technologique ), Etablissement Français du Sang Bretagne, EFS, Centre Hospitalier Universitaire [Rennes], Université Toulouse III - Paul Sabatier (UT3), Université Fédérale Toulouse Midi-Pyrénées, STROMALab, Centre National de la Recherche Scientifique (CNRS)-Ecole Nationale Vétérinaire de Toulouse (ENVT), Institut National Polytechnique (Toulouse) (Toulouse INP), Université Fédérale Toulouse Midi-Pyrénées-Université Fédérale Toulouse Midi-Pyrénées-Institut National Polytechnique (Toulouse) (Toulouse INP), Université Fédérale Toulouse Midi-Pyrénées-Université Fédérale Toulouse Midi-Pyrénées-Université Toulouse III - Paul Sabatier (UT3), Université Fédérale Toulouse Midi-Pyrénées-Etablissement Français du Sang-Institut National de la Santé et de la Recherche Médicale (INSERM), Etablissement Français du Sang Pyrénées Méditerranée, This work was supported by the ANR program (SAFE 2012) (ANR-11-RPIB-0012) whose recipients are NBi, SL, LS, KT and RP. NBi, SL, RP and KT are also supported with grants from the Université Rennes 1 (emerging scientific challenges 2013). CG is recipient of a doctoral fellowship from the French Ministry of Education and Research and from the FRM (Fondation pour la Recherche Médicale, FDT20130928015). KT and LS are also supported by ECELLFRANCE (ANR-11-INSB-005) and the European Center for Transplantation Sciences and Immunotherapy (IHU CESTI, ANR-10-IBHU-0005). RP is supported by AIS Rennes Métropole, INSERM (Institut National de la Santé et de la Recherche Médicale) and La Ligue Contre le Cancer (Grand Ouest)., ANR-11-RPIB-0012,SAFE,Production sécurisée de Cellules stromales du tissu adipeux pour la thérapie cellulaire(2011), Université Fédérale Toulouse Midi-Pyrénées-Université Fédérale Toulouse Midi-Pyrénées-Ecole Nationale Vétérinaire de Toulouse (ENVT), Université Fédérale Toulouse Midi-Pyrénées-Institut National de la Santé et de la Recherche Médicale (INSERM)-Etablissement Français du Sang-Centre National de la Recherche Scientifique (CNRS), Université de Rennes (UR), Université de Rennes (UR)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Structure Fédérative de Recherche en Biologie et Santé de Rennes ( Biosit : Biologie - Santé - Innovation Technologique ), Université de Toulouse (UT), Université de Toulouse (UT)-Université de Toulouse (UT)-Ecole Nationale Vétérinaire de Toulouse (ENVT), Université de Toulouse (UT)-Université de Toulouse (UT)-Institut National Polytechnique (Toulouse) (Toulouse INP), and Université de Toulouse (UT)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Etablissement Français du Sang-Centre National de la Recherche Scientifique (CNRS)

Subjects
Protein Stability, [SDV]Life Sciences [q-bio], Tumor Suppressor Proteins, Intracellular Signaling Peptides and Proteins, Nuclear Proteins, Sumoylation, Hypoxia-Inducible Factor 1, alpha Subunit, Models, Biological, Protein Inhibitors of Activated STAT, Cell Hypoxia, Adipose Tissue, Proteolysis, Humans, Cell Lineage, Original Article, Gene Silencing, Stromal Cells, Poly-ADP-Ribose Binding Proteins, Cells, Cultured, Inhibitor of Growth Protein 1, DNA Damage
Abstract

International audience; Hypoxic niches help maintain mesenchymal stromal cell properties, and their amplification under hypoxia sustains their immature state. However, how MSCs maintain their genomic integrity in this context remains elusive, since hypoxia may prevent proper DNA repair by downregulating expression of BRCA1 and RAD51. Here, we find that the ING1b tumor suppressor accumulates in adipose-derived stromal cells (ADSCs) upon genotoxic stress, owing to SUMOylation on K193 that is mediated by the E3 small ubiquitin-like modifier (SUMO) ligase protein inhibitor of activated STAT protein γ (PIAS4). We demonstrate that ING1b finely regulates the hypoxic response by triggering HIF1α proteasomal degradation. On the contrary, when mutated on its SUMOylation site, ING1b failed to efficiently decrease HIF1α levels. Consistently, we observed that the adipocyte differentiation, generally described to be downregulated by hypoxia, was highly dependent on ING1b expression, during the early days of this process. Accordingly, contrary to what was observed with HIF1α, the absence of ING1b impeded the adipogenic induction under hypoxic conditions. These data indicate that ING1b contributes to adipogenic induction in adipose-derived stromal cells, and thus hinders the phenotype maintenance of ADSCs.

Published
2014
Full Text
View/download PDF

21. A randomized controlled clinical trial evaluating the performance and safety of platelets treated with MIRASOL pathogen reduction technology

Author

Cazenave, Jp, Folléa, G., Bardiaux, L., Boiron, Jm, Lafeuillade, B., Debost, M., Lioure, B., Harousseau, J.l., Deconinck, E., Tabrizi, R., Cahn, Jy, Michallet, M., Ambruso, D., Schots, Henri, Tissot, Jd, Sensebé, L., Kondo, T., Mccullough, J, Rebulla, Paolo, Escolar, G., Mintz, P., Heddle, Nm, Goodrich, Rp, Bruhwyler, J., Le, C., Cook, Rj, Stouch, B., and Hematology

Subjects
MIRASOL pathogen reduction technology, pathogen reduction of platelets, food and beverages
Abstract

BACKGROUND: Pathogen reduction of platelets (PRT-PLTs) using riboflavin and ultraviolet light treatment has undergone Phase 1 and 2 studies examining efficacy and safety. This randomized controlled clinical trial (RCT) assessed the efficacy and safety of PRT-PLTs using the 1-hour corrected count increment (CCI(1hour) ) as the primary outcome. STUDY DESIGN AND METHODS: A noninferiority RCT was performed where patients with chemotherapy-induced thrombocytopenia (six centers) were randomly allocated to receive PRT-PLTs (Mirasol PRT, CaridianBCT Biotechnologies) or reference platelet (PLT) products. The treatment period was 28 days followed by a 28-day follow-up (safety) period. The primary outcome was the CCI(1hour) determined using up to the first eight on-protocol PLT transfusions given during the treatment period. RESULTS: A total of 118 patients were randomly assigned (60 to PRT-PLTs; 58 to reference). Four patients per group did not require PLT transfusions leaving 110 patients in the analysis (56PRT-PLTs; 54 reference). A total of 541 on-protocol PLT transfusions were given (303 PRT-PLTs; 238 reference). The least square mean CCI was 11,725 (standard error [SE], 1.140) for PRT-PLTs and 16,939 (SE, 1.149) for the reference group (difference, -5214; 95% confidence interval, -7542 to -2887; p

Published
2010

31. Advancing approaches for bone regeneration using freshly shipped marrow human mesenchymal stromal/stem cell produced into several european cGMP facilities

Author

Veronesi, E., primary, Murgia, A., additional, Grisendi, G., additional, Caselli, A., additional, Piccinno, S., additional, Giordano, R., additional, Montemurro, T., additional, Schrezenmeier, H., additional, Rojewski, M.T., additional, Burin, P., additional, Sensebé, L., additional, Layrolle, P., additional, Catani, F., additional, Desantis, G., additional, Paolucci, P., additional, Burns, J.S., additional, and Dominici, M., additional

Published
2013
Full Text
View/download PDF

33. Donor selection and release criteria of cellular therapy products

Author

Eichler, H., primary, Schrezenmeier, H., additional, Schallmoser, K., additional, Strunk, D., additional, Nystedt, J., additional, Kaartinen, T., additional, Korhonen, M., additional, Fleury‐Cappellesso, S., additional, Sensebé, L., additional, Bönig, H., additional, Rebulla, P., additional, Giordano, R., additional, Lecchi, L., additional, Takanashi, M., additional, Watt, S. M., additional, Austin, E. B., additional, Guttridge, M., additional, McLaughlin, L. S., additional, Panzer, S., additional, and Reesink, H. W., additional

Published
2012
Full Text
View/download PDF

46. Culture and Use of Mesenchymal Stromal Cells in Phase I and II Clinical Trials

Author

Bourin Philippe, Sensebé Luc, Planat-Bénard Valérie, Roncalli Jérôme, Bura-Rivière Alessandra, and Casteilla Louis

Subjects
Internal medicine, RC31-1245
Abstract

Present in numerous tissues, mesenchymal stem cells/multipotent stromal cells (MSCs) can differentiate into different cell types from a mesoderm origin. Their potential has been extended to pluripotency, by their possibility of differentiating into tissues and cells of nonmesodermic origin. Through the release of cytokines, growth factors and biologically active molecules, MSCs exert important paracrine effects during tissue repair and inflammation. Moreover, MSCs have immunosuppressive properties related to non-HLA restricted immunosuppressive capacities. All these features lead to an increasing range of possible applications of MSCs, from treating immunological diseases to tissue and organ repair, that should be tested in phase I and II clinical trials. The most widely used MSCs are cultured from bone marrow or adipose tissue. For clinical trial implementation, BM MSCs and ADSCs should be produced according to Good Manufacturing Practices. Safety remains the major concern and must be ensured during culture and validated with relevant controls. We describe some applications of MSCs in clinical trials.

Published
2010
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results